总的来说，泽璟制药和复宏汉霖在创新药领域的研发策略和进展令人瞩目。这些新的药物分子设计思路不仅为患者带来了新的希望，也为整个行业的发展注入了新的动力。未来，随着更多创新药物的研发和上市，我们有理由相信，癌症和其他疾病的治疗将迎来更多的突破。 返回搜狐，查看更多 ...

当今社会，癌症成为全球范围内的重大健康问题，你知道吗？其实，不断有关于创新药物的突破性研究出现，可能会改变癌症的治疗现状。近期，泽璟制药与复宏汉霖在创新药峰会上分享了许多振奋人心的信息，预示着新疗法的到来，让我们一起来了解一下这些潜力药物和它们所代表的未来。 众所周知，肿瘤的治疗往往面临多重挑战，但泽璟制药的董事长盛泽林在会议中详细讲解了他们的研发策略，展示了如何有效应对这些难题。泽璟制药目前的五 ...

汉曲优在2024年4月和8月分别于美国和加拿大获批上市，并在2024年11月完成首批美国商业化发货，预计2025年将开始释放其美国市场潜力；同年汉曲优在巴西和墨西哥等拉美主流市场获批上市，中东地区完成沙特发货，成为该地区首个国产单抗生物类似药。

© 2025 American Heart Association, Inc. Department of Cell Biology and Anatomy (X.W., M.A., C.E.E.), University of South Carolina School of Medicine, Columbia ...

（3月12日《Nature》“TGFβ links EBV to multisystem inflammatory syndrome in children”） 研究人员发现，新冠康复儿童的血液中潜伏着异常高浓度的TGF-β——这种 ...

We recently published a list of 10 Best GARP Stocks to Buy Now. In this article, we are going to take a look at where Carpenter Technology Corp. (NYSE:CRS) stands against other best GARP stocks to ...

We recently published a list of 10 Best GARP Stocks to Buy Now. In this article, we are going to take a look at where Archrock Inc. (NYSE:AROC) stands against other best GARP stocks to buy now.

iShares MSCI USA Quality GARP ETF offers a balanced alternative to SPY, focusing on growth at a reasonable price with quality and value tilts. GARP's top-heavy allocation is more evenly ...

The iShares MSCI USA Quality GARP ETF changed its strategy and ticker on June 3, 2024, and now selects stocks based on a comprehensive system evaluating growth, value, and quality. Backtested ...

The Growth at a Reasonable Price (GARP) investment strategy focuses on identifying stocks with strong growth potential while ensuring they are not overvalued. This approach serves two primary ...